Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)

Market Cap	132.52B -66.5%
Revenue (ttm)	29.39M -34.4%
Net Income	-257.81M
EPS	-0.17
Shares Out	1.56B
PE Ratio	n/a
Forward PE	22.04
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,787,614
Open	85.30
Previous Close	85.20
Day's Range	81.60 - 86.20
52-Week Range	75.10 - 277.00
Beta	1.09
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 9, 2026

About TPE:6919

Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum’s disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for central obesity, hyperpigmentation, and skin aging, as well as offers dietary supplements. The company was incorporated in 2012 and is based in New Tai...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6919

Financial Performance

In 2025, TPE:6919's revenue was 38.04 million, a decrease of -14.40% compared to the previous year's 44.43 million. Losses were -351.92 million, -40.23% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 8, 2026

Data Sources Report a data error